ES2660288T3 - Derivados de quinolona - Google Patents
Derivados de quinolona Download PDFInfo
- Publication number
- ES2660288T3 ES2660288T3 ES13828997.0T ES13828997T ES2660288T3 ES 2660288 T3 ES2660288 T3 ES 2660288T3 ES 13828997 T ES13828997 T ES 13828997T ES 2660288 T3 ES2660288 T3 ES 2660288T3
- Authority
- ES
- Spain
- Prior art keywords
- hydroxy
- oxo
- carboxamido
- dihydroquinoline
- acetic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007660 quinolones Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000007502 anemia Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- -1 cycloalkanylalkyl Chemical group 0.000 abstract description 46
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 12
- 125000003118 aryl group Chemical group 0.000 abstract description 10
- 125000005842 heteroatom Chemical group 0.000 abstract description 7
- 229910052760 oxygen Inorganic materials 0.000 abstract description 7
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract description 6
- 229910052717 sulfur Inorganic materials 0.000 abstract description 5
- 229920006395 saturated elastomer Polymers 0.000 abstract description 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract description 3
- 125000002252 acyl group Chemical group 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 238000000034 method Methods 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 125000005336 allyloxy group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 2
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MXVBRRWLPNZAAJ-VIFPVBQESA-N (2s)-2-[(4-hydroxy-2-oxo-1-propoxyquinoline-3-carbonyl)amino]propanoic acid Chemical compound C1=CC=C2C(O)=C(C(=O)N[C@@H](C)C(O)=O)C(=O)N(OCCC)C2=C1 MXVBRRWLPNZAAJ-VIFPVBQESA-N 0.000 description 1
- PQUGTBHEJZVTPM-HNNXBMFYSA-N (2s)-2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]-3-methylbutanoic acid Chemical compound O=C1C(C(=O)N[C@@H](C(C)C)C(O)=O)=C(O)C2=CC=CC=C2N1OCC1CC1 PQUGTBHEJZVTPM-HNNXBMFYSA-N 0.000 description 1
- OGMYLSCPVCWCOB-KRWDZBQOSA-N (2s)-2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C=1C(N(OCC2CC2)C2=CC=CC=C2C=1O)=O)C1=CC=CC=C1 OGMYLSCPVCWCOB-KRWDZBQOSA-N 0.000 description 1
- JCSCDPOJLDEXLM-AWEZNQCLSA-N (2s)-2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]-4-methylpentanoic acid Chemical compound O=C1C(C(=O)N[C@@H](CC(C)C)C(O)=O)=C(O)C2=CC=CC=C2N1OCC1CC1 JCSCDPOJLDEXLM-AWEZNQCLSA-N 0.000 description 1
- NFLDLYYKSTYHBV-ZDUSSCGKSA-N (2s)-4-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]-2-hydroxybutanoic acid Chemical compound O=C1C(C(=O)NCC[C@H](O)C(O)=O)=C(O)C2=CC=CC=C2N1OCC1CC1 NFLDLYYKSTYHBV-ZDUSSCGKSA-N 0.000 description 1
- KCIDDQXSAVBNIT-UHFFFAOYSA-N 1-(cyclopropylmethoxy)-4-hydroxy-n-[2-(methanesulfonamido)-2-oxoethyl]-2-oxoquinoline-3-carboxamide Chemical compound O=C1C(C(=O)NCC(=O)NS(=O)(=O)C)=C(O)C2=CC=CC=C2N1OCC1CC1 KCIDDQXSAVBNIT-UHFFFAOYSA-N 0.000 description 1
- WQWWFASITSVPDU-UHFFFAOYSA-N 1-[(4-hydroxy-2-oxo-1-phenylmethoxyquinoline-3-carbonyl)amino]cyclopropane-1-carboxylic acid Chemical compound OC=1C2=CC=CC=C2N(OCC=2C=CC=CC=2)C(=O)C=1C(=O)NC1(C(=O)O)CC1 WQWWFASITSVPDU-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- RWYYCUSPFKSAHO-UHFFFAOYSA-N 2-[(1-cyclopentyloxy-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=C2N1OC1CCCC1 RWYYCUSPFKSAHO-UHFFFAOYSA-N 0.000 description 1
- RREOQYFNRSYKGV-UHFFFAOYSA-N 2-[(1-ethoxy-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(OCC)C2=C1 RREOQYFNRSYKGV-UHFFFAOYSA-N 0.000 description 1
- WRTIQJTZFYQPMD-UHFFFAOYSA-N 2-[(1-heptoxy-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(OCCCCCCC)C2=C1 WRTIQJTZFYQPMD-UHFFFAOYSA-N 0.000 description 1
- NUOBVOHOFNWDNI-UHFFFAOYSA-N 2-[(4,6-dihydroxy-2-oxo-1-propoxyquinoline-3-carbonyl)amino]acetic acid Chemical compound C1=C(O)C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(OCCC)C2=C1 NUOBVOHOFNWDNI-UHFFFAOYSA-N 0.000 description 1
- ZZFPJKYVGFOSSL-UHFFFAOYSA-N 2-[(4-hydroxy-1-methoxy-2-oxo-1,5-naphthyridine-3-carbonyl)amino]acetic acid Chemical compound C1=CN=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(OC)C2=C1 ZZFPJKYVGFOSSL-UHFFFAOYSA-N 0.000 description 1
- XIRJRLBBDMEUAS-UHFFFAOYSA-N 2-[(4-hydroxy-2-oxo-1-phenylmethoxy-6-phenylsulfanylquinoline-3-carbonyl)amino]acetic acid Chemical compound C=1C=C2N(OCC=3C=CC=CC=3)C(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1SC1=CC=CC=C1 XIRJRLBBDMEUAS-UHFFFAOYSA-N 0.000 description 1
- JIXNFYSYVXWYNX-UHFFFAOYSA-N 2-[(4-hydroxy-2-oxo-1-phenylmethoxy-6-pyridin-2-yloxyquinoline-3-carbonyl)amino]acetic acid Chemical compound C=1C=C2N(OCC=3C=CC=CC=3)C(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1OC1=CC=CC=N1 JIXNFYSYVXWYNX-UHFFFAOYSA-N 0.000 description 1
- LFTXYPKIUYJQNH-UHFFFAOYSA-N 2-[(4-hydroxy-2-oxo-1-phenylmethoxyquinoline-3-carbonyl)-methylamino]acetic acid Chemical compound O=C1C(C(=O)N(CC(O)=O)C)=C(O)C2=CC=CC=C2N1OCC1=CC=CC=C1 LFTXYPKIUYJQNH-UHFFFAOYSA-N 0.000 description 1
- LTIOGLVHBZZXPA-UHFFFAOYSA-N 2-[(4-hydroxy-2-oxo-1-phenylmethoxyquinoline-3-carbonyl)amino]-2-methylpropanoic acid Chemical compound O=C1C(C(=O)NC(C)(C)C(O)=O)=C(O)C2=CC=CC=C2N1OCC1=CC=CC=C1 LTIOGLVHBZZXPA-UHFFFAOYSA-N 0.000 description 1
- MLQJLPHIRAMYLU-UHFFFAOYSA-N 2-[(4-hydroxy-2-oxo-6-phenoxy-1-phenylmethoxyquinoline-3-carbonyl)amino]acetic acid Chemical compound C=1C=C2N(OCC=3C=CC=CC=3)C(=O)C(C(=O)NCC(=O)O)=C(O)C2=CC=1OC1=CC=CC=C1 MLQJLPHIRAMYLU-UHFFFAOYSA-N 0.000 description 1
- GCFNJXMSJCJJKZ-UHFFFAOYSA-N 2-[(4-hydroxy-2-oxo-6-phenyl-1-phenylmethoxyquinoline-3-carbonyl)amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC(C=3C=CC=CC=3)=CC=C2N1OCC1=CC=CC=C1 GCFNJXMSJCJJKZ-UHFFFAOYSA-N 0.000 description 1
- GFWRWTAVGLAZPL-UHFFFAOYSA-N 2-[(4-hydroxy-6-methylsulfonyl-2-oxo-1-phenylmethoxyquinoline-3-carbonyl)amino]acetic acid Chemical compound O=C1C(C(=O)NCC(O)=O)=C(O)C2=CC(S(=O)(=O)C)=CC=C2N1OCC1=CC=CC=C1 GFWRWTAVGLAZPL-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- LXNUHEADYMOVJN-UHFFFAOYSA-N 2-[[1-(1,3-benzoxazol-2-ylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC=C2OC(CON3C4=CC=CC=C4C(O)=C(C3=O)C(=O)NCC(=O)O)=NC2=C1 LXNUHEADYMOVJN-UHFFFAOYSA-N 0.000 description 1
- VTPNJOAZCZTYLP-UHFFFAOYSA-N 2-[[1-(2-amino-2-oxoethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(OCC(=O)N)C2=C1 VTPNJOAZCZTYLP-UHFFFAOYSA-N 0.000 description 1
- NQAYVCLXEWPNCL-UHFFFAOYSA-N 2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,7-naphthyridine-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=NC=C2N1OCC1CC1 NQAYVCLXEWPNCL-UHFFFAOYSA-N 0.000 description 1
- YVVCFZNRYUVYCS-UHFFFAOYSA-N 2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,8-naphthyridine-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CN=C2N1OCC1CC1 YVVCFZNRYUVYCS-UHFFFAOYSA-N 0.000 description 1
- IKRKQQLJYBAPQT-UHFFFAOYSA-N 2-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=C2N1OCC1CC1 IKRKQQLJYBAPQT-UHFFFAOYSA-N 0.000 description 1
- CHZFWZHPTHEMPB-UHFFFAOYSA-N 2-[[1-[(2,4-difluorophenyl)methoxy]-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=C2N1OCC1=CC=C(F)C=C1F CHZFWZHPTHEMPB-UHFFFAOYSA-N 0.000 description 1
- MMQNAJIYLVPOIO-UHFFFAOYSA-N 2-[[1-[(2,6-difluorophenyl)methoxy]-4-hydroxy-2-oxo-1,8-naphthyridine-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CN=C2N1OCC1=C(F)C=CC=C1F MMQNAJIYLVPOIO-UHFFFAOYSA-N 0.000 description 1
- AIUUIYINHXLJFT-UHFFFAOYSA-N 2-[[1-[(2-fluorophenyl)methoxy]-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=C2N1OCC1=CC=CC=C1F AIUUIYINHXLJFT-UHFFFAOYSA-N 0.000 description 1
- GYQJQKOORJLBOW-UHFFFAOYSA-N 2-[[4-hydroxy-1-(1,3-oxazol-2-ylmethoxy)-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=C2N1OCC1=NC=CO1 GYQJQKOORJLBOW-UHFFFAOYSA-N 0.000 description 1
- CLJURQZOGFJAEX-UHFFFAOYSA-N 2-[[4-hydroxy-1-(2-methoxyethoxy)-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(OCCOC)C2=C1 CLJURQZOGFJAEX-UHFFFAOYSA-N 0.000 description 1
- AZZQTFUDHTYVGV-UHFFFAOYSA-N 2-[[4-hydroxy-1-[(4-methoxyphenyl)methoxy]-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC(OC)=CC=C1CON1C(=O)C(C(=O)NCC(O)=O)=C(O)C2=CC=CC=C21 AZZQTFUDHTYVGV-UHFFFAOYSA-N 0.000 description 1
- IAPIIUFNZRPYSH-UHFFFAOYSA-N 2-[[4-hydroxy-1-[[4-(1,3-oxazol-2-yl)phenyl]methoxy]-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=C2N1OCC(C=C1)=CC=C1C1=NC=CO1 IAPIIUFNZRPYSH-UHFFFAOYSA-N 0.000 description 1
- WHYASILINQOOOE-UHFFFAOYSA-N 2-[[4-hydroxy-1-methoxy-2-oxo-6-(trifluoromethyl)quinoline-3-carbonyl]amino]acetic acid Chemical compound C1=C(C(F)(F)F)C=C2C(O)=C(C(=O)NCC(O)=O)C(=O)N(OC)C2=C1 WHYASILINQOOOE-UHFFFAOYSA-N 0.000 description 1
- GOFVYWMXXZBPOS-UHFFFAOYSA-N 2-[[4-hydroxy-2-oxo-1-[(4-phenylphenyl)methoxy]quinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=C2N1OCC(C=C1)=CC=C1C1=CC=CC=C1 GOFVYWMXXZBPOS-UHFFFAOYSA-N 0.000 description 1
- PNEONCXWDKMMJA-UHFFFAOYSA-N 2-[[4-hydroxy-2-oxo-1-[2-[4-(trifluoromethyl)phenyl]ethoxy]quinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=C2N1OCCC1=CC=C(C(F)(F)F)C=C1 PNEONCXWDKMMJA-UHFFFAOYSA-N 0.000 description 1
- AZQNCLSWUMWYHN-UHFFFAOYSA-N 2-[[4-hydroxy-2-oxo-1-[[4-(trifluoromethoxy)phenyl]methoxy]quinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC=CC=C2N1OCC1=CC=C(OC(F)(F)F)C=C1 AZQNCLSWUMWYHN-UHFFFAOYSA-N 0.000 description 1
- UVDRGZUFFDXSSL-UHFFFAOYSA-N 2-[[4-hydroxy-2-oxo-1-phenylmethoxy-6-(trifluoromethoxy)quinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC(OC(F)(F)F)=CC=C2N1OCC1=CC=CC=C1 UVDRGZUFFDXSSL-UHFFFAOYSA-N 0.000 description 1
- CAHHKQQPPLTDBH-UHFFFAOYSA-N 2-[[4-hydroxy-6-(4-methoxyphenyl)-2-oxo-1-phenylmethoxyquinoline-3-carbonyl]amino]acetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(N(OCC=2C=CC=CC=2)C(=O)C(C(=O)NCC(O)=O)=C2O)C2=C1 CAHHKQQPPLTDBH-UHFFFAOYSA-N 0.000 description 1
- HHSKTUWZCOHQGX-UHFFFAOYSA-N 2-[[4-hydroxy-6-(methanesulfonamido)-2-oxo-1-phenylmethoxyquinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(O)=O)=C(O)C2=CC(NS(=O)(=O)C)=CC=C2N1OCC1=CC=CC=C1 HHSKTUWZCOHQGX-UHFFFAOYSA-N 0.000 description 1
- SRFLMLIGVXRPRR-UHFFFAOYSA-N 2-[[6-benzoyl-4-hydroxy-2-oxo-1-[[4-(trifluoromethyl)phenyl]methoxy]quinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC(C(=O)C=3C=CC=CC=3)=CC=C2N1OCC1=CC=C(C(F)(F)F)C=C1 SRFLMLIGVXRPRR-UHFFFAOYSA-N 0.000 description 1
- LWRVFWSEZXUQLI-UHFFFAOYSA-N 2-[[6-cyano-1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid Chemical compound O=C1C(C(=O)NCC(=O)O)=C(O)C2=CC(C#N)=CC=C2N1OCC1CC1 LWRVFWSEZXUQLI-UHFFFAOYSA-N 0.000 description 1
- IPOVOSHRRIJKBR-UHFFFAOYSA-N 2-ethylpropanedioyl dichloride Chemical compound CCC(C(Cl)=O)C(Cl)=O IPOVOSHRRIJKBR-UHFFFAOYSA-N 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- BLESLFORBKTMRN-UHFFFAOYSA-N 3-[(4-hydroxy-2-oxo-1-phenylmethoxyquinoline-3-carbonyl)amino]propanoic acid Chemical compound O=C1C(C(=O)NCCC(=O)O)=C(O)C2=CC=CC=C2N1OCC1=CC=CC=C1 BLESLFORBKTMRN-UHFFFAOYSA-N 0.000 description 1
- XSYUCZFYRAXOIR-UHFFFAOYSA-N 3-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]propanoic acid Chemical compound O=C1C(C(=O)NCCC(=O)O)=C(O)C2=CC=CC=C2N1OCC1CC1 XSYUCZFYRAXOIR-UHFFFAOYSA-N 0.000 description 1
- FIAYXGKGFQFXLP-UHFFFAOYSA-N 4-hydroxy-2-oxo-n-[2-oxo-2-(thiophene-2-carbonylamino)ethyl]-1-phenylmethoxyquinoline-3-carboxamide Chemical compound O=C1N(OCC=2C=CC=CC=2)C2=CC=CC=C2C(O)=C1C(=O)NCC(=O)NC(=O)C1=CC=CS1 FIAYXGKGFQFXLP-UHFFFAOYSA-N 0.000 description 1
- GWNSOIVCUZWOGK-UHFFFAOYSA-N 4-hydroxy-n-[2-(methanesulfonamido)-2-oxoethyl]-2-oxo-1-phenylmethoxyquinoline-3-carboxamide Chemical compound O=C1C(C(=O)NCC(=O)NS(=O)(=O)C)=C(O)C2=CC=CC=C2N1OCC1=CC=CC=C1 GWNSOIVCUZWOGK-UHFFFAOYSA-N 0.000 description 1
- FYBWKACNRGWCTE-UHFFFAOYSA-N 5-[[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]pentanoic acid Chemical compound O=C1C(C(=O)NCCCCC(=O)O)=C(O)C2=CC=CC=C2N1OCC1CC1 FYBWKACNRGWCTE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- TWQWDZNCGPEIEL-UHFFFAOYSA-N C(C1=CC=CC=C1)ON1C(C(=C(C2=CC(=CC=C12)C1=NC=C(C=C1)OC)O)C(=O)NCC(=O)O)=O Chemical compound C(C1=CC=CC=C1)ON1C(C(=C(C2=CC(=CC=C12)C1=NC=C(C=C1)OC)O)C(=O)NCC(=O)O)=O TWQWDZNCGPEIEL-UHFFFAOYSA-N 0.000 description 1
- BFTQBBMXZITUDM-UHFFFAOYSA-N CC(C)(C)c1ccc(COn2c3ccccc3c(O)c(C(=O)NCC(O)=O)c2=O)cc1 Chemical compound CC(C)(C)c1ccc(COn2c3ccccc3c(O)c(C(=O)NCC(O)=O)c2=O)cc1 BFTQBBMXZITUDM-UHFFFAOYSA-N 0.000 description 1
- BYTCWJVGMBOUFO-UHFFFAOYSA-N CCCC(CCC)On1c2ccccc2c(O)c(C(=O)NCC(O)=O)c1=O Chemical compound CCCC(CCC)On1c2ccccc2c(O)c(C(=O)NCC(O)=O)c1=O BYTCWJVGMBOUFO-UHFFFAOYSA-N 0.000 description 1
- JONPMJYAGXKPAU-UHFFFAOYSA-N CCCOn1c2ccc(Oc3ccccc3)cc2c(O)c(C(=O)NCC(O)=O)c1=O Chemical compound CCCOn1c2ccc(Oc3ccccc3)cc2c(O)c(C(=O)NCC(O)=O)c1=O JONPMJYAGXKPAU-UHFFFAOYSA-N 0.000 description 1
- RBJCMLGWQHEMOF-UHFFFAOYSA-N CCOn1c2c(OC)cccc2c(O)c(C(=O)NCC(O)=O)c1=O Chemical compound CCOn1c2c(OC)cccc2c(O)c(C(=O)NCC(O)=O)c1=O RBJCMLGWQHEMOF-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-N Monoethyl malonic acid Chemical compound CCOC(=O)CC(O)=O HGINADPHJQTSKN-UHFFFAOYSA-N 0.000 description 1
- 101000987583 Mus musculus Eosinophil peroxidase Proteins 0.000 description 1
- HFSVMIJDONHCNZ-UHFFFAOYSA-N NS(=O)(=O)c1ccc2n(OCc3ccccc3)c(=O)c(C(=O)NCC(O)=O)c(O)c2c1 Chemical compound NS(=O)(=O)c1ccc2n(OCc3ccccc3)c(=O)c(C(=O)NCC(O)=O)c(O)c2c1 HFSVMIJDONHCNZ-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- SOBQSMFEVFMUOF-UHFFFAOYSA-N OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCCC(F)(F)F)c1=O Chemical compound OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCCC(F)(F)F)c1=O SOBQSMFEVFMUOF-UHFFFAOYSA-N 0.000 description 1
- DNCIHBIOCLVKEN-UHFFFAOYSA-N OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCc2ccc(nc2)C(F)(F)F)c1=O Chemical compound OC(=O)CNC(=O)c1c(O)c2ccccc2n(OCc2ccc(nc2)C(F)(F)F)c1=O DNCIHBIOCLVKEN-UHFFFAOYSA-N 0.000 description 1
- NTVWLHJZZNPMRP-UHFFFAOYSA-N OC(=O)CNC(=O)c1c(O)c2cccnc2n(OCCc2ccc(cc2)C(F)(F)F)c1=O Chemical compound OC(=O)CNC(=O)c1c(O)c2cccnc2n(OCCc2ccc(cc2)C(F)(F)F)c1=O NTVWLHJZZNPMRP-UHFFFAOYSA-N 0.000 description 1
- LOLRAIJESQEIEN-UHFFFAOYSA-N OC1=C(C(N(C2=CC=CC=C12)OC1=CC=C(C=C1)C(F)(F)F)=O)C(=O)NCC(=O)O Chemical compound OC1=C(C(N(C2=CC=CC=C12)OC1=CC=C(C=C1)C(F)(F)F)=O)C(=O)NCC(=O)O LOLRAIJESQEIEN-UHFFFAOYSA-N 0.000 description 1
- XSTIGCZNHKBWRL-UHFFFAOYSA-N OC1=C(C(N(C2=CC=CC=C12)OCC(F)(F)F)=O)C(=O)NCC(=O)O Chemical compound OC1=C(C(N(C2=CC=CC=C12)OCC(F)(F)F)=O)C(=O)NCC(=O)O XSTIGCZNHKBWRL-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- JGDHDCNNQCKOAI-UHFFFAOYSA-N ethyl 2-(cyclopropylmethoxyamino)benzoate Chemical compound CCOC(=O)C1=CC=CC=C1NOCC1CC1 JGDHDCNNQCKOAI-UHFFFAOYSA-N 0.000 description 1
- ZWGLDZCXDAKIFM-UHFFFAOYSA-N ethyl 2-(hydroxyamino)benzoate Chemical compound CCOC(=O)C1=CC=CC=C1NO ZWGLDZCXDAKIFM-UHFFFAOYSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- UZJBOHHDWXQTEF-UHFFFAOYSA-N pocl3 pyridine Chemical compound ClP(Cl)(Cl)=O.C1=CC=NC=C1 UZJBOHHDWXQTEF-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- YJBKVPRVZAQTPY-UHFFFAOYSA-J tetrachlorostannane;dihydrate Chemical compound O.O.Cl[Sn](Cl)(Cl)Cl YJBKVPRVZAQTPY-UHFFFAOYSA-J 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3600MU2012 | 2012-12-24 | ||
| IN3600MU2012 | 2012-12-24 | ||
| PCT/IN2013/000796 WO2014102818A1 (en) | 2012-12-24 | 2013-12-23 | Novel quinolone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2660288T3 true ES2660288T3 (es) | 2018-03-21 |
Family
ID=54148255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13828997.0T Active ES2660288T3 (es) | 2012-12-24 | 2013-12-23 | Derivados de quinolona |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9394300B2 (enExample) |
| EP (1) | EP2935221B1 (enExample) |
| JP (1) | JP6026013B2 (enExample) |
| KR (1) | KR101733901B1 (enExample) |
| CN (1) | CN104903295B (enExample) |
| AP (1) | AP2015008502A0 (enExample) |
| AR (1) | AR094300A1 (enExample) |
| AU (1) | AU2013368843B2 (enExample) |
| BR (1) | BR112015014222B1 (enExample) |
| CA (1) | CA2894636C (enExample) |
| CL (1) | CL2015001802A1 (enExample) |
| EA (1) | EA028402B1 (enExample) |
| ES (1) | ES2660288T3 (enExample) |
| IL (1) | IL239109B (enExample) |
| JO (1) | JO3781B1 (enExample) |
| MA (1) | MA38138A1 (enExample) |
| MX (1) | MX373392B (enExample) |
| MY (1) | MY175854A (enExample) |
| NZ (1) | NZ708605A (enExample) |
| PH (1) | PH12015501452B1 (enExample) |
| SG (1) | SG11201504458XA (enExample) |
| TR (1) | TR201802305T4 (enExample) |
| TW (1) | TWI598339B (enExample) |
| UA (1) | UA117122C2 (enExample) |
| WO (1) | WO2014102818A1 (enExample) |
| ZA (1) | ZA201503814B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016034108A1 (zh) * | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| WO2016045125A1 (en) | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
| CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CA3062972C (en) | 2017-05-09 | 2021-09-14 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| TW202200547A (zh) * | 2020-03-13 | 2022-01-01 | 印度商卡地拉保健有限公司 | 喹啉酮化合物的新穎鹽類 |
| EP4121009A4 (en) * | 2020-03-17 | 2024-04-17 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| EP4138825A1 (en) | 2020-04-20 | 2023-03-01 | Akebia Therapeutics Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| EP4157233A4 (en) * | 2020-05-29 | 2024-06-26 | Zydus Lifesciences Limited | TREATMENT OF PSORIASIS AND INFLAMMATORY SKIN DISEASES |
| CN115666517A (zh) * | 2020-06-01 | 2023-01-31 | 兹杜斯生命科学有限公司 | 炎性肠病的治疗 |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| BR112023018949A2 (pt) * | 2021-03-19 | 2023-10-17 | Zydus Lifesciences Ltd | Composto, uso do mesmo para tratar anemia falciforme e composição farmacêutica compreendendo o referido composto |
| EP4308089A4 (en) * | 2021-03-19 | 2025-02-26 | Zydus Lifesciences Limited | QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THEIR PREPARATION |
| WO2022238745A1 (en) * | 2021-05-14 | 2022-11-17 | Zydus Lifesciences Limited | Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors |
| TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
| CN113549011B (zh) * | 2021-08-10 | 2023-05-09 | 广东东阳光药业有限公司 | 德度司他的共晶或盐及其制备方法和用途 |
| WO2023042170A1 (en) * | 2021-09-20 | 2023-03-23 | Zydus Lifesciences Limited | Desidustat particles and compositions thereof |
| EP4539934A1 (en) * | 2022-06-24 | 2025-04-23 | Zydus Lifesciences Limited | Treatment for glomerular diseases |
| WO2024028744A1 (en) * | 2022-08-01 | 2024-02-08 | Zydus Lifesciences Limited | Treatment for aplastic anemia (aa) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| PL1644336T3 (pl) | 2003-06-06 | 2011-07-29 | Fibrogen Inc | Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny |
| CN101166745A (zh) * | 2005-03-02 | 2008-04-23 | 菲布罗根有限公司 | 噻吩并吡啶化合物和其使用方法 |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| JP5202327B2 (ja) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| AR059733A1 (es) * | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| CA2647596C (en) * | 2006-04-04 | 2012-06-12 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as hif modulators |
| WO2007136990A2 (en) * | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| EP2044068A4 (en) * | 2006-07-17 | 2010-07-21 | Merck Sharp & Dohme | 1-HYDROXY Naphthyridine Compounds as Anti- HIV Drugs |
| WO2008076425A1 (en) | 2006-12-18 | 2008-06-26 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| ES2442847T3 (es) * | 2007-04-18 | 2014-02-13 | Amgen, Inc | Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa |
| EP2136810A4 (en) * | 2007-04-18 | 2012-01-04 | Merck Sharp & Dohme | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS |
| AU2008248234B2 (en) * | 2007-05-04 | 2011-02-03 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| AU2008248165B2 (en) * | 2007-05-04 | 2011-12-08 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| AU2008251031B2 (en) * | 2007-05-16 | 2013-12-19 | Norman Terry Cowper | System and method for maximising solids concentration of slurry pumped through a pipeline |
| AU2008329746A1 (en) * | 2007-11-30 | 2009-06-04 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| JP2011513222A (ja) * | 2008-02-25 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | テトラヒドロチエノピリジン |
| JP2011513223A (ja) * | 2008-02-25 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | テトラヒドロ−１ｈ−ピロロ縮合ピリドン |
| CN101951777A (zh) * | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢呋喃并吡啶酮 |
| WO2009158315A1 (en) * | 2008-06-25 | 2009-12-30 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| DK2455381T5 (en) | 2009-07-17 | 2015-02-09 | Japan Tobacco Inc | Triazolopyridinforbindelse and its effect as an inhibitor of prolyl hydroxylase and induce erythropoietin production by |
| EP2467361A1 (de) * | 2009-08-20 | 2012-06-27 | Vifor (International) Ag | Neue chinolin-hepcidin-antagonisten |
| EP2670750B1 (en) | 2011-02-02 | 2016-09-14 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor |
| WO2013043621A1 (en) | 2011-09-23 | 2013-03-28 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| EP2810944A1 (en) * | 2012-01-31 | 2014-12-10 | Toyama Chemical Co., Ltd. | Heterocyclic compound having anti-hiv activity |
-
2013
- 2013-12-23 AU AU2013368843A patent/AU2013368843B2/en active Active
- 2013-12-23 US US14/652,024 patent/US9394300B2/en active Active
- 2013-12-23 BR BR112015014222-2A patent/BR112015014222B1/pt active IP Right Grant
- 2013-12-23 SG SG11201504458XA patent/SG11201504458XA/en unknown
- 2013-12-23 CA CA2894636A patent/CA2894636C/en active Active
- 2013-12-23 ES ES13828997.0T patent/ES2660288T3/es active Active
- 2013-12-23 TW TW102147766A patent/TWI598339B/zh active
- 2013-12-23 EA EA201591195A patent/EA028402B1/ru not_active IP Right Cessation
- 2013-12-23 AP AP2015008502A patent/AP2015008502A0/xx unknown
- 2013-12-23 CN CN201380067856.4A patent/CN104903295B/zh active Active
- 2013-12-23 NZ NZ708605A patent/NZ708605A/en unknown
- 2013-12-23 UA UAA201506784A patent/UA117122C2/uk unknown
- 2013-12-23 JO JOP/2013/0383A patent/JO3781B1/ar active
- 2013-12-23 KR KR1020157016080A patent/KR101733901B1/ko active Active
- 2013-12-23 WO PCT/IN2013/000796 patent/WO2014102818A1/en not_active Ceased
- 2013-12-23 TR TR2018/02305T patent/TR201802305T4/tr unknown
- 2013-12-23 MX MX2015008233A patent/MX373392B/es active IP Right Grant
- 2013-12-23 EP EP13828997.0A patent/EP2935221B1/en active Active
- 2013-12-23 MY MYPI2015001457A patent/MY175854A/en unknown
- 2013-12-23 JP JP2015548889A patent/JP6026013B2/ja active Active
- 2013-12-27 AR ARP130105055A patent/AR094300A1/es active IP Right Grant
-
2015
- 2015-05-27 ZA ZA2015/03814A patent/ZA201503814B/en unknown
- 2015-05-29 MA MA38138A patent/MA38138A1/fr unknown
- 2015-06-01 IL IL239109A patent/IL239109B/en active IP Right Grant
- 2015-06-22 CL CL2015001802A patent/CL2015001802A1/es unknown
- 2015-06-23 PH PH12015501452A patent/PH12015501452B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2660288T3 (es) | Derivados de quinolona | |
| US11274102B2 (en) | Compounds useful in HIV therapy | |
| JP6448647B2 (ja) | アザ−ピリドン化合物およびその用途 | |
| US10220030B2 (en) | Amino-quinolines as kinase inhibitors | |
| JP5269085B2 (ja) | ヒト免疫不全ウイルス複製のインヒビター | |
| JP7243959B2 (ja) | イソオキサゾール誘導体、その製造方法、及びその使用 | |
| KR20250133486A (ko) | THRβ 수용체 효능제 화합물 및 그의 제조 방법 및 용도 | |
| WO2009062289A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| EA037626B1 (ru) | Соединения бензо[b]тиофена как агонисты sting | |
| WO2014141110A2 (en) | Aminonitriles as kynurenine pathway inhibitors | |
| SG175331A1 (en) | Inhibitors of human immunodeficiency virus replication | |
| WO2014149494A1 (en) | Sanguinarine analog pp2c inhibitors for cancer treatment | |
| TWI829325B (zh) | Ahr促效劑 | |
| CN102199133B (zh) | 2’,2-双噻唑非核苷类化合物及其制备方法、药物组合物和作为肝炎病毒抑制剂的用途 | |
| JP6035334B2 (ja) | 抗マラリア療法のための置換２−アルキル−１−オキソ−ｎ−フェニル−３−ヘテロアリール−１，２，３，４−テトラヒドロイソキノリン−４−カルボキサミド | |
| CA2289100A1 (en) | Quinoline derivatives as pde iv and/or tnf inhibitors | |
| JP2018087173A (ja) | 悪性脳腫瘍治療薬 | |
| CA3233233A1 (en) | Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof | |
| WO2024222630A1 (zh) | 喹诺酮衍生物及其在抗肿瘤中的应用 | |
| JP5946540B2 (ja) | ３−ヒドロキシキノリン誘導体の新規合成法 | |
| HK40028203A (zh) | 化合物 | |
| CN114502538A (zh) | 用于治疗和预防乙型肝炎病毒感染的经取代的3,4-二氢喹唑啉 | |
| Patel et al. | Synthesis and Study of Some New 2-Imino-3-[Carboxamido o-hydroxyphenyl]-5-Arylidene-4-Thiazolidinone as Antibacterial Agents | |
| HK40028203B (zh) | 化合物 | |
| KR20080011402A (ko) | 디히드로피리딘 유도체 |